glp 1 weight loss studies Healthy maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial GLP-1R Agonists for Weight Loss

Obesity affects 42% of adults in the United States and is strongly associated with major cardiovascular disease risk factors, including high blood pressure, abnormal cholesterol levels, and insulin resistance, making effective obesity treatment a critical public health priority.

Flat pricing and fast approval shine, but media claims raise trust flags.

Appetite Control Naturally curbs cravings and supports portion control

Major kudos to Chad Janis and the entire Grns team

Metabolic Support Improves glucose regulation and insulin function

At 12 months, weight loss persisted at around 4%, with variability between agents, most notably liraglutide